Johnson & Johnson Raises 2026 Outlook, Sees Drug Deals Cutting 2027 EPS

Johnson & Johnson (NYSE: JNJ ) on Tuesday reported third-quarter 2026 results that beat Wall Street estimates. The company also raised its full-year sales and adjusted earnings guidance. 53. 25 billion.

1%. GAAP earnings totaled 9 cents per share, reflecting approximately $7 billion in charges related to a proposed talc litigation resolution, the acquisition of Firefly Bio and a strategic collaboration with Sail Biomedicines. 9%. Growth was driven by oncology treatments Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze and Erleada.

Immunology drug Tremfya and neuroscience treatments Spravato and Caplyta also contributed. However, declining Stelara sales reduced growth by approximately 690 basis points. Sales of Simponi/Simponi Aria, Remicade, Imbruvica and Opsumit/Opsynvi also fell. 5% operational growth.

Electrophysiology products and Shockwave supported cardiovascular sales, while contact lenses and orthopedic trauma products also contributed. S. The company said it is taking steps to improve performance while remaining confident in MedTech's long-term prospects. 08 consensus estimate.

29 billion. CEO Joaquin Duato said the company remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. He also outlined Johnson & Johnson's ambition to become the world's leading oncology company by 2030, with projected oncology sales exceeding $50 billion. 36 per share.

The deals are also expected to weigh on 2026 adjusted earnings by 64 cents per share. However, management remains confident in its long-term growth outlook, driven by investments in its drug pipeline. 38 at the time of publication on Tuesday, according to Pro data. Image via Shutterstock Read Also: Elon Musk Fires Back at Broadcom CEO Hock Tan's AI Investment Warning: 'No Crying in the Casino'